Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic NSCLC with Actionable Genomic Alterations By Ogkologos - January 27, 2025 430 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPION-Lung05 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Drug Shows Promise in Slowing Progression of Smoldering Myeloma to Cancer June 7, 2019 EMA Recommends Extension of Therapeutic Indications for Lisocabtagene Maraleucel February 28, 2025 Trastuzumab Deruxtecan Shows Antitumour Activity and Durable Responses in Heavily Pretreated... May 16, 2024 Man Pushes Daughter To Safety Before Speeding Car Hits Him Instead:... March 29, 2019 Load more HOT NEWS Single Dose of HPV Vaccine Yields Long-Term Protection from Many Cancer-Causing... Drinking Alcohol, Often Heavily, Common among People with Cancer and Long-Term... Early cancer diagnosis and COVID-19: unpicking the impact of the pandemic Επικοινωνία
